KR20230079514A - 암 면역요법용 dna 백신을 제조하기 위한 방법 - Google Patents

암 면역요법용 dna 백신을 제조하기 위한 방법 Download PDF

Info

Publication number
KR20230079514A
KR20230079514A KR1020237018125A KR20237018125A KR20230079514A KR 20230079514 A KR20230079514 A KR 20230079514A KR 1020237018125 A KR1020237018125 A KR 1020237018125A KR 20237018125 A KR20237018125 A KR 20237018125A KR 20230079514 A KR20230079514 A KR 20230079514A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237018125A
Other languages
English (en)
Korean (ko)
Inventor
하인즈 루베나우
Original Assignee
엔이씨 온코이뮤니티 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔이씨 온코이뮤니티 에이에스 filed Critical 엔이씨 온코이뮤니티 에이에스
Publication of KR20230079514A publication Critical patent/KR20230079514A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020237018125A 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법 Ceased KR20230079514A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16001550.9 2016-07-13
EP16001550 2016-07-13
KR1020197002050A KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002050A Division KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Publications (1)

Publication Number Publication Date
KR20230079514A true KR20230079514A (ko) 2023-06-07

Family

ID=56418345

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237018125A Ceased KR20230079514A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법
KR1020197002050A Ceased KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197002050A Ceased KR20190027834A (ko) 2016-07-13 2017-07-12 암 면역요법용 dna 백신을 제조하기 위한 방법

Country Status (13)

Country Link
US (2) US10821163B2 (enExample)
EP (1) EP3484503A1 (enExample)
JP (2) JP7098599B2 (enExample)
KR (2) KR20230079514A (enExample)
CN (1) CN109475614A (enExample)
AU (1) AU2017295004B2 (enExample)
BR (1) BR112019000657A2 (enExample)
CA (1) CA3028549A1 (enExample)
IL (1) IL263568A (enExample)
MX (1) MX2019000415A (enExample)
RU (1) RU2019100079A (enExample)
SG (1) SG11201811258UA (enExample)
WO (1) WO2018011289A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7712060B2 (ja) * 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規vegfr-2ターゲット免疫療法アプローチ
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
CN112638408A (zh) * 2018-09-05 2021-04-09 万科斯蒙股份有限公司 用于联合疗法的靶向新抗原的dna疫苗
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR20220128638A (ko) 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
US20250340919A1 (en) * 2022-06-30 2025-11-06 Shimadzu Corporation Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091898A1 (en) 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3892295T (pt) * 2011-05-24 2023-06-01 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacinas individualizadas para o cancro
MX359315B (es) 2012-07-05 2018-09-25 Vaximm Ag Vacuna de adn para usarse en pacientes con cancer pancreatico.
MX364922B (es) 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
KR20160130979A (ko) * 2013-12-18 2016-11-15 백심 게엠베하 암 면역요법을 위한 신규한 msln 표적화 dna 백신
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091898A1 (en) 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains

Also Published As

Publication number Publication date
US20190183996A1 (en) 2019-06-20
MX2019000415A (es) 2019-03-28
JP2022097591A (ja) 2022-06-30
WO2018011289A1 (en) 2018-01-18
CN109475614A (zh) 2019-03-15
US10821163B2 (en) 2020-11-03
US20220072112A1 (en) 2022-03-10
JP7098599B2 (ja) 2022-07-11
JP2019521154A (ja) 2019-07-25
AU2017295004B2 (en) 2020-08-13
RU2019100079A (ru) 2020-08-13
KR20190027834A (ko) 2019-03-15
IL263568A (en) 2019-01-31
BR112019000657A2 (pt) 2019-04-24
CA3028549A1 (en) 2018-01-18
EP3484503A1 (en) 2019-05-22
SG11201811258UA (en) 2019-01-30
AU2017295004A1 (en) 2019-01-03
US11590215B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
AU2017295004B2 (en) Process for the production of a DNA vaccine for cancer immunotherapy
KR102090612B1 (ko) 췌장암 환자용 dna 백신
CN107995868B (zh) 用于联合治疗的vegfr-2靶向dna疫苗
KR20190125481A (ko) 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
JP2024167172A (ja) 併用療法用dnaワクチンを標的とするネオアンチゲン
CN109906087A (zh) 用于联合治疗的wt1靶向dna疫苗
AU2018222777B9 (en) Novel VEGFR-2 targeting immunotherapy approach
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
RU2759227C2 (ru) ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신
AU2019334131B2 (en) Neoantigen targeting DNA vaccine for combination therapy
CN120944823A (zh) 特异性结合Claudin18.2的嵌合抗原受体免疫细胞及其应用

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230526

Application number text: 1020197002050

Filing date: 20190122

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240202

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250220

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D